During a Community Case Forum event, Antoinette R. Tan, MD, MHS, discussed the DESTINY-Breast04 and DESTINY-Breast06 trials ...

With significant survival improvements seen, the FDA has granted approval to retifanlimab for the first-line treatment of ...

BCB-276 has earned regenerative medicine advanced therapy designation from the FDA in diffuse intrinsic pontine glioma, an ...

During a live event, Xiuning Le, MD, PhD, discussed clinical trials of supportive care for infusion reaction and skin rash ...

During a live event, Pedro C. Barata, MD, MSc, discussed the case of a patient with advanced clear cell renal cell carcinoma ...

Samuraciclib improved progression-free survival in HR+ advanced breast cancer patients without TP53 mutations or liver ...

The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end ...

In the phase 2/3 REFRαME-O1 trial, luveltamab tazevibulin showed encouraging responses in patients with ovarian cancer with ...

Mack Roach III, MD, discusses concerns about how tariffs and restrictions on international collaboration could negatively affect cancer research and treatment.

Stuart J. Schnitt, MD, discussed how AI enhances cancer diagnoses and the need for professional oversight, ethical clarity, and equitable adoption.

Nini Wu, MD, MBA, discusses the future of technology in community oncology, particularly highlighting the pervasive topic of artificial intelligence.

Belrestotug plus dostarlimab showed no progression-free survival benefit in NSCLC, leading GSK and iTeos to discontinue all ...